Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2025-06-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
2024年年度股东大会、2025年第一次A股类别股东大会及2025年第一次H股类别股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) and the 2025 first A-share and H-share category shareholders meetings of the company 康龙化成 (Beijing) New Drug Technology Co., Ltd. It includes voting results for multiple proposals, attendance details, legal opinions on the meeting's legality, and references to the meeting dates and procedures. The content is focused on the official voting results and resolutions from the shareholders' meetings rather than the full annual report or financial statements. The document is lengthy and comprehensive but is clearly an announcement of the voting results and resolutions from the AGM and related shareholder meetings. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-06-20 Chinese
北京市中伦律师事务所关于公司2024年年度股东大会、2025年第一次A股类别股东大会及2025年第一次H股类别股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the company's 2024 Annual General Meeting (AGM) and subsequent category-specific shareholder meetings in 2025. It details the legality and validity of the meeting process and voting outcomes but does not contain the actual annual report or financial statements. The document is focused on the AGM and related shareholder meetings, providing legal assurance on the meeting's conduct and results. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting, including legal opinions on the meeting process and results.
2025-06-20 Chinese
关于股东解除一致行动关系的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company 康龙化成 (Beijing) New Drug Technology Co., Ltd. regarding the解除一致行动关系 (termination of concerted action relationship) among certain shareholders. It details changes in the ordinary partners and executive partners of employee shareholding platforms, clarifies that the actual control of the company remains unchanged, and confirms compliance with relevant laws and stock exchange regulations. There is no financial data, no report attached or referenced as being published, and no mention of earnings, audit, or management reports. The document is a regulatory announcement about shareholder relationship changes, specifically about解除一致行动关系, which is a shareholder-related disclosure. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Major Shareholding Notification (MRQ) because it does not report a change in shareholding levels, but rather a change in shareholder relationships and control status.
2025-06-20 Chinese
H股公告
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipts issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, treasury shares, and other share-related movements for the month ending May 31, 2025. The document is titled as a monthly report and contains detailed tables of share capital and share movements, but it is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital and securities movements, typical of disclosures required by the Hong Kong Stock Exchange. The document length is 3363 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about share capital and securities movements that does not fit other more specific categories.
2025-06-04 Chinese
关于公司实际控制人股份质押和解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the company's actual controllers. It details the number of shares pledged and released, the dates, and the impact on the company's control and operations. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging activities by major shareholders, which fits the category of Major Shareholding Notification (MRQ). The document length is 3242 characters, which is typical for such announcements. Therefore, the appropriate classification is MRQ.
2025-06-03 Chinese
关于境外子公司参与境外股权投资基金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by 康龙化成（北京）新药技术股份有限公司 regarding its wholly-owned overseas subsidiary's participation as a limited partner in an overseas equity investment fund. It details the investment amount, the fund's structure, partners, investment scope, management fees, profit distribution, and risks. The document is a formal disclosure of a capital investment transaction by the company, not a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly results. It is a regulatory announcement about a financing/investment activity involving capital commitment and fund participation. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (5576 characters) and detailed content support this classification with high confidence.
2025-05-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.